Embecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.2 USD | +3.27% | +38.27% | -24.99% |
05-09 | Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup | DJ |
05-09 | Transcript : Embecta Corp., Q2 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.99% | 793M | |
-4.72% | 182B | |
+3.96% | 112B | |
-2.93% | 68.58B | |
+6.30% | 51.58B | |
+8.02% | 44.24B | |
+9.45% | 43.65B | |
+26.18% | 32.46B | |
+20.94% | 25.99B | |
+0.57% | 25.61B |
- Stock Market
- Equities
- EMBC Stock
- News Embecta Corp.
- Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch Pump